210 related articles for article (PubMed ID: 37815603)
1. Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor promoting and tumor suppressor roles in ovarian cancer.
Price ZK; Lokman NA; Sugiyama M; Koya Y; Yoshihara M; Oehler MK; Kajiyama H; Ricciardelli C
Cell Mol Life Sci; 2023 Oct; 80(11):320. PubMed ID: 37815603
[TBL] [Abstract][Full Text] [Related]
2. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2.
Chao A; Lin CY; Lee YS; Tsai CL; Wei PC; Hsueh S; Wu TI; Tsai CN; Wang CJ; Chao AS; Wang TH; Lai CH
Oncogene; 2012 Feb; 31(6):764-75. PubMed ID: 21725366
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer.
Ricciardelli C; Ween MP; Lokman NA; Tan IA; Pyragius CE; Oehler MK
BMC Cancer; 2013 Oct; 13():476. PubMed ID: 24124770
[TBL] [Abstract][Full Text] [Related]
4. Disabled-2 (
Price ZK; Lokman NA; Yoshihara M; Kajiyama H; Oehler MK; Ricciardelli C
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614139
[TBL] [Abstract][Full Text] [Related]
5. Detection of a specific pattern of hyaluronan oligosaccharides and their binding proteins in human ovarian tumour.
Kolapalli SP; Nunna V; Thomas A; Mortha KK; Banerjee SD; Boregowda RK
Cell Biochem Funct; 2016 Jun; 34(4):217-25. PubMed ID: 27001487
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells.
Bourguignon LY; Peyrollier K; Gilad E; Brightman A
J Biol Chem; 2007 Jan; 282(2):1265-80. PubMed ID: 17092940
[TBL] [Abstract][Full Text] [Related]
7. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.
Ween MP; Oehler MK; Ricciardelli C
Int J Mol Sci; 2011 Jan; 12(2):1009-29. PubMed ID: 21541039
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma.
Journo-Gershfeld G; Kapp D; Shamay Y; Kopeček J; David A
Pharm Res; 2012 Apr; 29(4):1121-33. PubMed ID: 22350800
[TBL] [Abstract][Full Text] [Related]
9. Cell surface expression of hyaluronan on human ovarian cancer cells inversely correlates with their adhesion to peritoneal mesothelial cells.
Tamada Y; Takeuchi H; Suzuki N; Aoki D; Irimura T
Tumour Biol; 2012 Aug; 33(4):1215-22. PubMed ID: 22392500
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion.
Bourguignon LY; Wong G; Earle C; Krueger K; Spevak CC
J Biol Chem; 2010 Nov; 285(47):36721-35. PubMed ID: 20843787
[TBL] [Abstract][Full Text] [Related]
11. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
12. Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors.
Rizzardi AE; Vogel RI; Koopmeiners JS; Forster CL; Marston LO; Rosener NK; Akentieva N; Price MA; Metzger GJ; Warlick CA; Henriksen JC; Turley EA; McCarthy JB; Schmechel SC
Cancer; 2014 Jun; 120(12):1800-9. PubMed ID: 24668563
[TBL] [Abstract][Full Text] [Related]
13. Loss of Disabled-2 Expression in Pancreatic Cancer Progression.
Hocevar BA
Sci Rep; 2019 May; 9(1):7532. PubMed ID: 31101868
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression.
Bourguignon LY; Gilad E; Rothman K; Peyrollier K
J Biol Chem; 2005 Mar; 280(12):11961-72. PubMed ID: 15655247
[TBL] [Abstract][Full Text] [Related]
15. Colorectal cancer-associated ~ 6 kDa hyaluronan serves as a novel biomarker for cancer progression and metastasis.
Zhang G; Lu R; Wu M; Liu Y; He Y; Xu J; Yang C; Du Y; Gao F
FEBS J; 2019 Aug; 286(16):3148-3163. PubMed ID: 31004406
[TBL] [Abstract][Full Text] [Related]
16. Disabled-2 inactivation is an early step in ovarian tumorigenicity.
Fazili Z; Sun W; Mittelstaedt S; Cohen C; Xu XX
Oncogene; 1999 May; 18(20):3104-13. PubMed ID: 10340382
[TBL] [Abstract][Full Text] [Related]
17. Binding of ovarian cancer cells to immobilized hyaluronic acid.
Catterall JB; Gardner MJ; Jones LM; Turner GA
Glycoconj J; 1997 Nov; 14(7):867-9. PubMed ID: 9511993
[TBL] [Abstract][Full Text] [Related]
18. Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells.
Sheng Z; Sun W; Smith E; Cohen C; Sheng Z; Xu XX
Oncogene; 2000 Oct; 19(42):4847-54. PubMed ID: 11039902
[TBL] [Abstract][Full Text] [Related]
19. CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration.
Bourguignon LY; Zhu H; Shao L; Chen YW
J Biol Chem; 2001 Mar; 276(10):7327-36. PubMed ID: 11084024
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy.
Edelman R; Assaraf YG; Levitzky I; Shahar T; Livney YD
Oncotarget; 2017 Apr; 8(15):24337-24353. PubMed ID: 28212584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
